课题基金 / 基金详情

GENETIC SUSCEPTIBILITY TO LIPID-LOWERING DRUG-INDUCED MYOPATHIES

GENETIC SUSCEPTIBILITY TO LIPID-LOWERING DRUG-INDUCED MYOPATHIES
对降脂药物引起的肌病的遗传易感性
批准号:
7952194
负责人:
MICHAEL H. WEISMAN
金额:
$0.09万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-12-01 至 2009-11-30

项目摘要

项目成果

MICHAEL H. WEISMAN的其他基金

相关文献

中文摘要
翻译
这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金, 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究的目的是确定接受HMG-CoA还原酶抑制剂治疗并发展为肌病的个体是否有更高的导致代谢性肌肉疾病的基因突变患病率。200名患者将被招募到这项研究中。
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of the study is to determine if individuals who are treated with HMG-CoA reductase inhibitors and develop myopathy have a higher prevalence of genetic mutations causing metabolic muscle diseases. Two-hundred patients will be recruited into the study.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
RHEUMATOID ARTHRITIS ASSOCIATED AUTOIMMUNITY IN HIGH RISK POPULATIONS
A COMPREHENSIVE MODEL OF SEVERITY IN OUTCOMES IN ANKYLOSING SPONDYLITIS
INFLAMMATORY MARKERS IN THE STOOL AND SERUM OF PATIENTS WITH ANKYLOSING SPONDYLI
GENETIC SUSCEPTIBILITY TO LIPID-LOWERING DRUG-INDUCED MYOPATHIES